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Uncoupling Protein-2 Negatively Regulates Insulin
Secretion and Is a Major Link between Obesity,
 Cell Dysfunction, and Type 2 Diabetes
Introduction
Glucose homeostasis is critical to the well-being of
mammals and is maintained, in large part, by pancreatic
 cells which secrete insulin in proportion to increasing
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UCP3 (Boss et al., 1997; Gong et al., 1997; Vidal-Puiglates insulin secretion. Uncoupling protein-2 (UCP2)
et al., 1997) are recently discovered members of themediates mitochondrial proton leak, decreasing ATP
mitochondrial inner membrane carrier family with highproduction. In the present study, we assessed UCP2’s
homology to the brown adipose tissue-specific protonrole in regulating insulin secretion. UCP2-deficient
transporter, UCP1 (reviewed in Klingenberg and Huang,mice had higher islet ATP levels and increased glu-
1999). UCP3 is expressed primarily in skeletal musclecose-stimulated insulin secretion, establishing that
while UCP2 is expressed widely, but at varying levels,UCP2 negatively regulates insulin secretion. Of patho-
in a number of tissues and cell types, including the
physiologic significance, UCP2 was markedly upregu-
pancreatic  cell. UCP1 leaks protons into the mitochon-
lated in islets of ob/ob mice, a model of obesity-induced drial matrix, bypassing ATP synthase, releasing energy
diabetes. Importantly, ob/ob mice lacking UCP2 had stored within the protonmotive force as heat (Klingen-
restored first-phase insulin secretion, increased se- berg and Huang, 1999). In rodents, UCP1 plays an impor-
rum insulin levels, and greatly decreased levels of gly- tant role in mediating cold exposure-induced thermo-
cemia. These results establish UCP2 as a key compo- genesis (Enerback et al., 1997) and is also a likely
nent of  cell glucose sensing, and as a critical link regulator of diet-induced thermogenesis (Himms-Hagen,
between obesity,  cell dysfunction, and type 2 dia- 1989). Given the high homology of UCP2 and UCP3 to
betes. UCP1, it has been assumed that they also have proton
transport activity. Studies in which UCP2 and UCP3
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reconstituted into proteoliposomes (Echtay et al., 2001; high levels of Ucp2 mRNA. Of note, Ucp2 mRNA is re-
duced in pancreatic islets isolated from heterozygousJaburek et al., 1999) indicate a proton leak role for these
new UCPs. In strong support of this, it has been shown (/) animals. As expected, UCP2 protein was unde-
tectable in mitochondria isolated from spleen of Ucp2that mitochondria isolated from skeletal muscle of Ucp3
gene knockout mice have decreased proton leak (Gong gene knockout mice (Figure 1d).
et al., 2000; Vidal-Puig et al., 2000).
A recent study described the creation of Ucp2 gene Effect of UCP2 Deficiency on Body Weight
knockout mice (Arsenijevic et al., 2000). This study and Cold Exposure-Induced Thermogenesis
showed that UCP2 deficiency did not effect body weight. Given the role of the brown fat-specific UCP1 in regulat-
Of interest, it was reported that UCP2-deficient mice ing cold-induced thermogenesis (Enerback et al., 1997),
are resistant to Toxoplasma gondii infection. This resis- it has been postulated that UCP2 might play a similar
tance is due to enhanced toxoplasmacidal activity of role. To assess this possibility, body weights and body
infected UCP2-deficient macrophages, thought to be temperature during cold exposure (4C) were assessed
due to increased production of reactive oxygen species. in control (/) and UCP2-deficient (/) mice. Animals
It has been proposed that UCP2 limits production of were housed four per cage (23C, except during cold
reactive oxygen species by decreasing the mitochon- exposure) with a 12 hr light/dark cycle and had ad libitum
drial membrane potential (reviewed in Skulachev, 1998). access to chow and water. Body weights were equiva-
Given the proton leak activity of UCP2 and its pre- lent in control and UCP2-deficient mice (data not
dicted negative effect on ATP synthesis in  cells, UCP2 shown). Also, body temperature during cold exposure
could be a negative regulator of insulin secretion. In was similar in control and UCP2-deficient mice (data
support of this view, adenovirally mediated overexpres- not shown). These findings suggest that UCP2 does not
sion of UCP2 in isolated pancreatic rat islets decreased regulate body weight or cold exposure-induced thermo-
ATP content (Chan et al., 2001) and inhibited glucose- genesis under the conditions studied, or that alternative
stimulated insulin secretion (Chan et al., 1999, 2001). mechanisms compensated for the absence of UCP2. Of
Similar results were reported following overexpression note, no upregulation of Ucp3 mRNA in heart, muscle,
of UCP2 in insulin-secreting, INS-1 cultured cells (Hong or white fat, or Ucp1 mRNA in brown fat was observed
et al., 2001). However, seemingly conflicting data were in UCP2-deficient mice (data not shown).
obtained using a related approach in which UCP2 was
overexpressed in islets isolated from obese ZDF rats UCP2-Deficient Pancreatic Islets Have Increased
(Wang et al., 1999). These animals lack normal leptin ATP Levels and Increased Insulin Secretion
receptors, develop obesity-induced type 2 diabetes, In order to evaluate the direct effect of UCP2 deficiency
and have defective glucose-stimulated insulin secretion on ATP levels and insulin secretion, pancreatic islets
(Unger, 1995). In apparent contrast to the study in normal were isolated from control and knockout mice, cultured
rat islets (Chan et al., 1999), UCP2 overexpression in overnight in 11 mM glucose, and then incubated on the
ZDF islets improved glucose-stimulated insulin secre- next day with varying concentrations of glucose. UCP2-
tion (Wang et al., 1999). These “gain-of-function” over- deficient islets, when compared to wild-type islets, had
expression studies suggest that UCP2 may play a role increased concentrations of ATP when incubated in 5.5
in regulating insulin secretion. However, the nature of mM and 11 mM glucose and secreted 2 to 3 times more
this effect in vivo, and in different physiologic and patho- insulin when incubated in 5.5 mM and 25 mM glucose
physiologic situations, is not known. Also, it is not known (Figure 2). Prior to isolation of islets, total pancreatic
whether endogenous levels of UCP2, as opposed to insulin content was equal in control versus UCP2-defi-
ectopically overexpressed levels of UCP2, have similar cient mice (data not shown). Similarly, following incuba-
negative effects on insulin secretion. tion of islets, total islet insulin content was equal in
To determine the physiologic function of endogenous control versus UCP2-deficient islets (data not shown).
levels of UCP2 in regulating insulin secretion, we gener- Also, islet cell number was unchanged as assessed by
ated and studied Ucp2 gene knockout mice. Our find- DNA content (ng/islet: /, 7.8  0.9 and /, 7.9 
ings indicate that UCP2 is an important negative regula- 2.2). These results demonstrate that incubated islets
tor of insulin secretion. Also, these studies show that from UCP2-deficient mice have increased ATP levels
induction of UCP2 causes  cell dysfunction in obese, and increased insulin secretion.
diabetic, ob/ob mice. Overall, these findings are likely
to have important implications for the pathogenesis of UCP2-Deficient Mice Have Higher Serum Insulin
obesity-induced diabetes in humans. and Lower Blood Glucose Levels
In order to assess effects of UCP2 deficiency on pancre-
atic insulin secretion in vivo, blood was obtained fromResults
fed and fasted control (/), heterozygous (/), and
homozygous (/) littermates. In the fed state, homozy-Ucp2 Gene Knockout Mice Lack Ucp2 mRNA
and UCP2 Protein gous (/) animals had 2.8-fold higher serum insulin
and 18% lower blood glucose levels (Figure 3a). In het-Gene targeting in embryonic stem cells was used to
generate UCP2-deficient mice (Figure 1). Homozygous erozygous animals (/), insulin and glucose levels
were intermediate, being elevated by 2.0-fold and de-(/) animals lack an intact Ucp2 gene (Figure 1b) and
fail to express intact Ucp2 mRNA (Figure 1c) in all tissues creased by 11%, respectively. The intermediate effect
observed in heterozygotes is consistent with the de-tested, including heart, kidney, spleen, white adipose
tissue, and pancreatic islets, which normally express creased expression of Ucp2 mRNA in islets (Figure 1c)
UCP2: A Negative Regulator of Insulin Secretion
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Figure 1. Generation of Mice Lacking UCP2
(a) Ucp2 wild-type allele, Ucp2 gene targeting construct, and Ucp2 targeted allele. Arrows refer to PCR primers used to genotype mice (see
[b]). Solid bar represents SphI-SacI DNA fragment used as a Southern blot hybridization probe.
(b) PCR genotyping of mice. Genotyping was performed using multiplex PCR. The knockout allele primers amplify a 300 bp PCR product
while the wild-type allele primers amplify a 600 bp PCR product. WT  wild-type (/), HT  heterozygote (/), and KO  knockout (/).
(c) Ucp2 mRNA. Individual tissues or pooled islets isolated from six mice of each genotype were used for RNA extraction. A Northern blot
analysis was performed using a full-length rat Ucp2 cDNA hybridization probe.
(d) UCP2 protein. Western blot analysis was used to detect UCP2 protein in mitochondria isolated from spleen.
and is particularly noteworthy since it indicates that rela- found to be elevated in UCP2-deficient mice (Figure 3b),
indicating that increased insulin levels in UCP2-deficienttively small changes in UCP2 activity (i.e., a 50% reduc-
tion) affect insulin secretion. In the fasted state, blood animals are due to increased secretion and not due to
decreased insulin clearance.glucose and insulin levels fell in both control and homo-
zygous animals (Figure 3a) with glucose values being In order to rule out the unlikely possibility that in-
creased insulin secretion was secondary to increasedequal in homozygous and control fasted mice. Insulin
levels, however, remained 3-fold higher in homozygous resistance to insulin action, insulin tolerance tests were
performed (1 U insulin/kg mouse, Figure 3c). These stud-versus control fasted animals. To rule out the possibility
that increased insulin levels are due to decreased insulin ies showed that sensitivity to exogenously administered
insulin was unaltered in UCP2-deficient mice. Additionalclearance, as opposed to increased insulin secretion,
serum C-peptide levels in the fed state were assessed. insulin tolerance tests were performed using a lower
dose of insulin (0.5 U/kg mouse) and similar results wereC-peptide is created during proinsulin processing and
is secreted along with insulin. The mechanism for C-pep- obtained (data not shown).
To investigate the dynamic response of UCP2-defi-tide clearance from the blood, however, is distinct from
insulin (Zavaroni et al., 1987). C-peptide levels were cient mice to increased glucose concentrations, glucose
Figure 2. ATP Levels and Rates of Insulin Se-
cretion from Isolated Pancreatic Islets
(a) ATP levels. Following overnight culture,
islets were exposed to 5.5 or 11.0 mM glu-
cose for 90 min and then assessed for con-
centrations of ATP. n per group: WT  7 and
KO  6.
(b) Insulin secretion. Following overnight cul-
ture, islets were exposed to 5.5 or 25 mM
glucose and insulin release was assessed. n
per group: WT  9 and KO  8.
Results are expressed as mean SE. * p




Figure 3. Glucose and Insulin Homeostasis in Wild-Type, Heterozygous, and UCP2 Knockout Male Mice
(a) Ambient serum insulin and blood glucose levels in fed and fasted wild-type (WT), heterozygous (HT), and knockout (KO) mice. Blood was
obtained from fed and overnight fasted animals between 8 am and noon. Fed study, n per group: WT  16, HT  21, and KO  6. Fasted
study, n per group: WT  7 and KO  8.
(b) Serum C-peptide levels in fed wild-type and UCP2 KO mice. n per group: WT  9 and KO  9.
(c) Insulin tolerance test (ITT). Following 6 hr without food, mice were injected with 1 U/kg of insulin (porcine insulin, #SL 144-7B, Eli Lilly,
Indianapolis, IN), i.p. (time 0). Blood glucose values were assessed before and 15, 30, 45, 60, and 90 min into the ITT. n per group: WT  5
and KO  7.
(d) Intraperitoneal glucose tolerance test (IPGTT). Following an overnight fast, mice were injected with 1g/kg of glucose, i.p. (time 0). Blood
glucose (left panel) and serum insulin (right panel) values were assessed before and 5, 15, and 30 min into the IPGTT. n per group: WT  8
and KO  6.
All results are expressed as mean  SE. *  p  0.05, **  p  0.01, and ***  p  0.001 versus WT, unpaired, two-tailed t test.
tolerance tests were performed (Figure 3d). Following mately 300 mg/dl in both groups (experimental design
shown in Figure 4a). Tracers were also infused so thatan exogenous load of glucose (1 g glucose/kg mouse/
i.p.), UCP2-deficient mice had a markedly reduced ex- whole-body glucose uptake and hepatic glucose pro-
duction could be monitored. The infusions successfullycursion of blood glucose levels, consistent with a greater
 cell response. Serum insulin levels started higher in increased plasma glucose levels equally in both groups
(Figure 4b). Of note, the UCP2-deficient mice requiredUCP2-deficient mice, increased to a level higher than
wild-type mice at the 5 min point, and then increased significantly higher glucose infusion rates in order to
increase glucose levels by the same magnitude (Figurefurther by the 15 and 30 min points, but to a level approx-
imately equal to that observed in the wild-type mice. 4c). Importantly, the insulin secretion response was sub-
stantially larger in UCP2-deficient mice (Figure 4d), prov-While the insulin levels were not statistically higher than
ing that UCP2-deficient mice have increased glucose-wild-type mice at the 15 and 30 min points, these equiva-
stimulated insulin secretion in vivo. Of interest, the needlent values were seen with substantially lower glucose
for a greater glucose infusion rate in UCP2-deficientlevels, indicating that UCP2-deficient mice had a rela-
mice was due to increased suppression of hepatic glu-tively greater insulin secretion response given their
cose production (Figure 4e) and not due to increasedlower glucose stimulus. These findings are consistent
uptake of glucose into muscle, fat, and other tissueswith increased glucose-stimulated insulin secretion in
(Figure 4f). The greater effect on hepatic glucose pro-UCP2-deficient mice.
duction is presumably due to the higher levels of insulin
obtained in the portal circulation.
Hyperglycemic Clamp Studies Demonstrate
that UCP2-Deficient Mice Have Increased Ucp2 mRNA and Protein Is Upregulated in Obese,
Insulin Secretion in Response to Equal Diabetic, ob/ob Mice
Increases in Blood Glucose Levels Given that UCP2 is a negative regulator of insulin secre-
Wild-type and UCP2-deficient, fasted mice were infused tion, it is important to assess UCP2 expression in models
with varying concentrations of glucose with the purpose of inadequate  cell function. To address this issue,
pancreatic islets were isolated from control (/) andof increasing plasma glucose levels equally, to approxi-
UCP2: A Negative Regulator of Insulin Secretion
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Figure 4. Hyperglycemic Clamp Studies
(a) Hyperglycemic clamp protocol. A 10 Ci bolus of [3-3H]glucose tracer was administered at time 60 min, followed by a constant infusion
rate of 0.1 Ci/min. At time 0, glucose was infused at a variable rate of 25–50 mg/min/kg with the aim of increasing plasma glucose levels in
both wild-type (WT) and knockout (KO) mice to 300 mg/dl.
Plasma glucose levels (b), glucose infusion rates (c), plasma insulin levels (d), hepatic glucose production (e), and whole-body glucose uptake
(f) before and during the hyperglycemic clamp. All results are expressed as mean  SE. n per group: WT  10 and KO  8. *  p  0.05
versus WT, unpaired, two-tailed t test.
obese (ob/ob) mice. Serum insulin levels were elevated these animals have blood glucose levels in the diabetic
range, indicating that their  cell response was inade-33-fold in obese ob/ob mice (Figure 5a), consistent with
the extreme levels of insulin resistance observed with quate. Of note, Ucp2 mRNA and protein were signifi-
cantly increased in ob/ob pancreatic islets (Figures 5bthis model. However, despite their hyperinsulinemia,
Figure 5. Blood Glucose, Serum Insulin, and
Pancreatic Islet Ucp2 mRNA and UPC2 Pro-
tein in Control and ob/ob Mice
Blood and pancreatic islets were obtained
from four control (/) and four ob/ob,
4-month-old male mice in the fed state.
(a) Blood glucose and serum insulin results
are expressed as mean  SE. ***  p 0.001
versus WT, unpaired, two-tailed t test.
(b) Islets from each genotype were pooled
and RNA was extracted for Northern blot
analysis.
(c) Islets from each genotype were pooled
and protein lysates were used for immuno-
logical detection of UCP2 and -tubulin.
Cell
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Figure 6. Glucose and Insulin Homeostasis in Male ob/ob Mice with (/) or without (/) UCP2
All study subjects were the F1 offspring of mice heterozygous for both the ob and Ucp2 alleles. Study subjects are as follows: wild-type (WT)
mice (/ at both the ob and Ucp2 loci), ob/ob mice (ob/ob at the ob locus and / at the Ucp2 locus), and ob/ob/ko mice (ob/ob at the
ob locus and / at the Ucp2 locus).
Body weight (a), fed blood glucose (b), and serum insulin (c) concentrations were assessed. n per group: WT  9, ob/ob  7, and ob/
ob/ko  9.
(d) Insulin tolerance test (ITT). Following 8 hr without food, mice were injected with 2 U/kg of insulin, i.p. (time 0). Blood glucose values were
assessed before and 15, 30, 45, 60, and 90 min into the ITT. n per group: ob/ob  5 and ob/ob/KO  5.
(e) Intraperitoneal glucose tolerance test (IPGTT). Following an overnight fast, mice were injected with 1 g/kg of glucose, i.p. (time 0). Blood
glucose (left panel) and serum insulin (right panel) values were assessed before and 15, 30, 60, and 90 min into the IPGTT. n per group: ob/
ob  5 and ob/ob/KO  6.
All results are expressed as mean  SE. *  p  0.05, **  p  0.01, and ***  p  0.001 versus ob/ob, unpaired, two-tailed t test..
and 5c). Given that UCP2 negatively regulates insulin UCP2 could be due to either increased insulin secretion,
decreased insulin resistance, or some combination ofsecretion, it can be hypothesized that increased UCP2
expression in  cells limits  cell function in response the two. Insulin tolerance tests were performed to as-
sess effects on insulin resistance (Figure 6d). Theseto hyperglycemia, thereby promoting the development
of diabetes. studies showed that sensitivity to exogenously adminis-
tered insulin was not improved in ob/ob mice lacking
UCP2. Thus, improved glycemia in ob/ob mice deficientDeficiency of UCP2 Markedly Improves Diabetes
in UCP2 must be due, in large part, to improved  cellin ob/ob Mice
function.In order to critically test the hypothesis that induction
To investigate the dynamic response of ob/ob miceof UCP2 in pancreatic islets of ob/ob mice impairs 
with or without UCP2 to increased glucose concentra-cell function and causes diabetes, Ucp2 gene knockout
tions, glucose tolerance tests were performed. Follow-and ob/ob mice were crossed. Of interest, UCP2 defi-
ing an exogenous glucose load, ob/ob mice had a mark-ciency had no effect on the obesity of ob/ob mice (Figure
edly abnormal, increased excursion of blood glucose6a). In striking contrast, UCP2 deficiency markedly re-
levels, consistent with their diabetic state (Figure 6e,duced the hyperglycemia of ob/ob mice (Figure 6b). Of
left panel). Of note, this abnormal response was dramati-note, insulin levels were found to be significantly higher
cally improved in ob/ob mice lacking UCP2, indicatingin ob/ob mice lacking UCP2 compared with ob/ob mice
that the diabetic state of these animals was amelioratedwith intact UCP2 at the age of 7, 9, and 11 weeks, and
by UCP2 deficiency. As has previously been observedhigher but not statistically significant at the age of 5
(Beloff-Chain et al., 1975), insulin levels fell in ob/obweeks (Figure 6c). These elevated insulin levels were
mice during the glucose tolerance test (Figure 6e, rightobserved despite the fact that blood glucose values
panel). In striking contrast, insulin levels rose signifi-were markedly lower at each age. These studies indicate
cantly at the 15 min point in ob/ob mice lacking UCP2.that ob/ob mice lacking UCP2 have improved  cell
This qualitative change in responsiveness demonstratesfunction, as evidenced by higher serum insulin levels in
that the abnormal function of ob/ob  cells is dramati-the face of markedly reduced blood glucose levels.
Improvement in glycemia of ob/ob mice deficient in cally improved when UCP2 is absent.
UCP2: A Negative Regulator of Insulin Secretion
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Discussion iologic and pathophysiologic perturbations are likely to
have important effects on insulin secretion.
Both insulin resistance and  cell dysfunction are impor-
tant in the pathogenesis of type 2 diabetes mellitus. UCP2 Is a Link between Obesity and  Cell Dysfunction
Insulin resistance, in isolation, can be compensated for in Obesity-Induced Type 2 Diabetes
by increased insulin secretion as evidenced by humans Given that UCP2 is a negative regulator of insulin secre-
with insulin receptor mutations (reviewed in Taylor, tion and that relatively small changes in UCP2 levels
1992). Similarly, impaired glucose-stimulated insulin se- significantly impact on insulin secretion, we hypothe-
cretion by  cells, in the absence of insulin resistance, sized that increased UCP2 expression in obesity might
does not cause frank diabetes as demonstrated by mice be an important link between obesity and the develop-
heterozygous for glucokinase deficiency (reviewed in ment of type 2 diabetes. Consistent with this notion,
Matschinsky et al., 1998) and mice completely lacking Ucp2 mRNA and UCP2 protein were found to be mark-
KATP channels (Miki et al., 1998; Seghers et al., 2000). In edly increased in islets of ob/ob animals, a mouse model
individuals destined to develop type 2 diabetes,  cells of obesity-induced type 2 diabetes. These animals have
are unable to meet the insulin resistance-induced de- extreme insulin resistance secondary to marked obesity
mand for increased insulin secretion, resulting in hyper- which leads to a 10- to 30-fold increase in  cell mass
glycemia due to a relative deficiency in circulating insulin and a similar increase in serum insulin levels (Gepts et
levels (reviewed in Kahn, 2000). In common forms of type al., 1960; Hellman et al., 1961). While the  cell insulin
2 diabetes, which is usually associated with obesity, the secretion response of ob/ob mice is significant, it is in
molecular basis for  cell dysfunction is not known. large part due to the marked expansion of  cell mass.
Excess fatty acids are thought to play a major role in Despite this large increase in  cell mass,  cell function
promoting the development of obesity-induced type 2 in ob/ob mice is inadequate since blood glucose levels
diabetes. Experimentally induced elevations in fatty are markedly elevated in these animals.
acids cause insulin resistance in skeletal muscle and To critically evaluate the role of UCP2 in promoting
increase hepatic glucose production (Boden and Jadali, type 2 diabetes in ob/ob mice, obese mice with or with-
1991; Boden et al., 1991; Shulman, 2000). In addition, out UCP2 were generated. UCP2 deficiency had no ef-
longer-term exposure to elevated fatty acids (	 24 hr) fect on the obesity of ob/ob mice. In contrast, ob/ob
negatively impacts on insulin secretion (Sako and Grill, mice lacking UCP2 were found to have dramatically im-
1990; Zhou and Grill, 1995). The mechanism for this proved blood glucose levels and higher serum insulin
effect is largely unknown, but may involve fatty acid- levels. The existence of higher serum insulin levels in
induced alterations in expression of proteins controlling the face of markedly reduced blood glucose concentra-
 cell metabolism (Brun et al., 1997; Segall et al., 1999), tions, and thus reduced stimulation for insulin secretion,
possibly UCP2 as will be discussed later. clearly demonstrates that ob/ob mice lacking UCP2
have greatly improved cell function. This view is further
supported by the results of glucose tolerance testsUCP2 Is a Negative Regulator of Insulin Secretion
Previous studies have shown that UCP2 has proton leak which revealed that ob/ob mice lacking UCP2 have in-
creased serum insulin levels following an exogenousactivity (Echtay et al., 2001; Fleury et al., 1997; Jaburek
et al., 1999; Rial et al., 1999). Despite this, UCP2 appears glucose load. This is in striking contrast to ob/ob mice
which fail to increase insulin levels following administra-not to be required for cold exposure-induced thermo-
genesis or body weight regulation. These findings are tion of glucose (Beloff-Chain et al., 1975; Brichard et al.,
1990; and Figure 6e). Thus, the unresponsiveness of ob/in agreement with an earlier investigation of Ucp2 gene
knockout mice (Arsenijevic et al., 2000). Instead, the ob  cells to exogenous glucose is dramatically im-
proved by UCP2 deficiency. It is interesting to note thatfindings of the present study clearly demonstrate that
UCP2 plays an important role in negatively regulating the improvement caused by UCP2 deficiency is most
prominent for the defect in first-phase insulin secretion.glucose-stimulated insulin secretion. When incubated
in vitro, pancreatic islets isolated from UCP2-deficient Loss of first-phase insulin secretion is one of the earliest
detectable  cell abnormalities observed in individualsmice have increased ATP levels, the intracellular stimu-
lus for insulin secretion, and secrete more insulin. Also, destined to develop diabetes and is thought to play an
important role in the development of type 2 diabeteswhen studied in vivo, UCP2-deficient mice secrete more
insulin in response to similar increases in blood glucose (reviewed in Poitout and Robertson, 1996). Overall,
these findings demonstrate that induction of UCP2 playslevels. Thus, UCP2, by virtue of its proton leak activity
and the consequent decrease in ATP production, down- a pathogenic role in the development of obesity-induced
type 2 diabetes in ob/ob mice.regulates the ability of  cells to secrete insulin in re-
sponse to glucose (Figure 7a). The fact that heterozy- Certain aspects of the glucose tolerance test (Figure
6e) raise the possibility that insulin action, in additiongous mice have intermediate blood glucose and insulin
levels illustrates that UCP2 is at an important control to insulin secretion, may also be improved in ob/ob mice
lacking UCP2. While these animals, compared with ob/point in the metabolic pathway regulating insulin secre-
tion. Similar gene dosage effects have been observed ob mice, had higher insulin levels at the 15 min point,
insulin levels were actually lower at the 30, 60, and 90for glucokinase, a  cell hexokinase at the first step of
glucose metabolism for which an important glucose- min points. These lower insulin levels could be indicative
of improved insulin action. Alternatively, the lower insu-sensing role has clearly been established (Matschinsky
et al., 1998). These findings also demonstrate that rela- lin values at the later time points could be due to the
fact that glucose concentration, the stimulus for insulintively small changes in UCP2 activity secondary to phys-
Cell
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Figure 7. UCP2, Insulin Secretion, and the
Pathogenesis of Obesity-Induced Type 2 Dia-
betes
(a) UCP2 negatively regulates insulin secre-
tion by decreasing the amount of ATP gener-
ated from glucose metabolism. Glucose is
oxidized generating NADH and FADH2 which
donate electrons to the electron transport
chain. Protons are pumped out by complexes
I, III, and IV of the electron transport chain
creating a proton electrochemical gradient
(
H). Protons may reenter the mitochon-
drial matrix via ATP synthase (F0F1), with en-
ergy being used to generate ATP from ADP
and Pi. Protons may also reenter via UCP2,
with energy being released in the form of
heat. In pancreatic  cells, increased ATP or
ATP/ADP ratio inhibits the KATP channel, de-
creasing plasma membrane potential (),
leading to an influx of Ca2 and secretion of
insulin. Increased ATP/ADP ratio also pro-
motes insulin secretion via mechanisms inde-
pendent of altered membrane potential. Ab-
breviations: ANC, adenine nucleotide carrier;
C, cytochrome C; Q, ubiquinone.
(b) Role of UCP2 in promoting obesity-
induced type 2 diabetes. Induction of UCP2
in  cells in the obese state impairs function
of the expanded  cell mass, leading to the
development of type 2 diabetes (see text for
further details).
secretion, was substantially reduced at these time However, fatty acids are likely to be involved since addi-
tion of fatty acids to cultured cells (Cortez-Pinto et al.,points in ob/ob mice lacking UCP2 (210–255 mg/dl ver-
sus 420 mg/dl in ob/ob mice). If an improvement in 1999; Reilly and Thompson, 2000), including cultured 
cells (Lameloise et al., 2001), upregulates UCP2 expres-insulin action is present, it is unlikely to be the primary
cause of reduced hyperglycemia in UCP2-deficient ob/ sion. As discussed earlier, long-term exposure of ani-
mals, incubated pancreatic islets, or cultured  cells toob mice. This is because ambient serum insulin levels
were found to be higher in these animals (Figure 6c). If fatty acids impairs glucose-stimulated insulin secretion
(Brun et al., 1997; Sako and Grill, 1990; Segall et al.,improved insulin sensitivity was the primary event, then
circulating insulin concentrations would be substantially 1999; Zhou and Grill, 1995). Recently, it was shown that
this effect in cultured  cells is associated with inductionlower, as is the case in ob/ob mice treated with the
insulin-sensitizing, PPAR agonist rosiglitazone. Rosig- of UCP2 (Lameloise et al., 2001). Given that chronic
exposure to fatty acids impairs  cell function and in-litazone-treated ob/ob mice have lower blood glucose
concentrations and dramatically reduced (80%–90% duces UCP2 and that UCP2 is upregulated in islets of
obese ob/ob mice (present study), and in mice (C.-Y.Z.lower) serum insulin levels (Chao et al., 2000). Alterna-
tively, improved insulin action could be secondary to and B.B.L., unpublished data) and rats (Chan et al., 2001)
fed a high fat diet, it is likely that exposure to excessreduced hyperglycemia. It has previously been estab-
lished that poorly controlled diabetes exacerbates insu- fatty acids is the initiator of obesity-induced, UCP2-
mediated  cell dysfunction.lin resistance due to effects of hyperglycemia on insulin
target tissues (i.e., “glucotoxicity”) (DeFronzo, 1988). In
summary, our data strongly supports an important role Model for Obesity-Induced Type 2 Diabetes:
for UCP2-dependent effects in mediating obesity-induced Important Role for UCP2
 cell dysfunction. However, additional effects on insulin This study demonstrates that UCP2 expressed at en-
action cannot be ruled out. dogenous levels in pancreatic  cells negatively regu-
lates insulin secretion. The mechanism for this effect
is summarized in Figure 7a. Based upon the findingsUpregulation of UCP2 in Obesity
The mechanism by which UCP2 is increased in  cells in presented in this report, as well as other studies, we
propose the following model for obesity-induced typeobesity-induced type 2 diabetes is presently unknown.
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detected by Western blotting (monoclonal anti--tubulin antibody,2 diabetes (Figure 7b). Obesity leads to the development
Boehringer-Mannheim, Germany). Bands were visualized with theof insulin resistance in muscle, fat, and liver, which leads
enhanced chemiluminescence system (Amersham).to  cell hyperplasia and, consequently, hyperinsulin-
emia. Impairments in expansion of  cell mass contrib-
ute to the development of diabetes in ZDF rats and in Isolated Pancreatic Islet Studies
Pancreatic islets were isolated according to a method used for ratsdb/db mice on the C57BL/KS background (Coleman,
(Cawthorn and Chan, 1991), except that the total exposure to type1982; Pick et al., 1998; Unger, 1995). This defective re-
XI collagenase (Worthington Biochemical Co., NJ) was 30 min andsponse is caused by unidentified differences in the ge-
the Ficoll gradient was altered to layers of 25%, 23%, 21%, and
netic background of these animals. Obesity also induces 11%. Islets were harvested from the 11%–21% interface. Islets were
UCP2 expression in  cells, which impairs glucose-stim- cultured in RPMI medium containing 11.0 mM glucose and supple-
ulated insulin secretion by the expanded  cell mass. mented with 1% penicillin-streptomycin, 7.5% fetal bovine serum
(all from Gibco/BRL, Burlington, ON), and 10 mM Hepes (Sigma).The present study clearly demonstrates that UCP2-
After culturing for 20–24 hr, the islets were transferred to microcen-mediated impaired function of the expanded  cell mass
trifuge tubes, pelleted (800 g for 5 min), and the medium aspiratedcontributes importantly to the inadequate insulin re-
and replaced with 1.0 ml DME medium containing 1% gelatin and
sponse and consequent hyperglycemia of ob/ob mice. glucose as indicated in the Results section. For insulin secretion
Together, abnormalities in insulin sensitivity,  cell studies, the islets were incubated three per tube. For determination
expansion, and  cell function account for the hyperin- of ATP levels, the islets were incubated 50 per tube. After incubation
at 37C for 90 min, the islets were centrifuged. The supernatant wassulinemia and hyperglycemia of type 2 diabetes. Finally,
collected and assayed for insulin (Rat Insulin RIA Kit, cat. #RI-13K,these findings raise the possibility that inhibitors of
Linco Res. Inc., St. Charles, MO), using mouse insulin as a standard.UCP2 activity, by increasing insulin secretion, could of-
The pellet was assessed for ATP concentrations using a luciferase-
fer a novel means of treating type 2 diabetes. based assay (Ronner et al., 1999). Islet DNA was measured using
the CyQYANT kit (Moleuclar Probes, Eugene, OR).
Experimental Procedures
Generation of Ucp2 Gene Knockout Mice Blood Glucose, Serum Insulin, and Serum
Ucp2 genomic clones were obtained after screening a P1 c129/SVJ C-Peptide Concentrations
genomic library (Genome Systems Inc., St. Louis, MO). A replace- Blood glucose levels were assessed using a glucometer (One touch,
ment targeting construct was prepared in which Ucp2 sequence Lifescan, Milpitas, CA). Serum insulin concentrations were assessed
between introns 2 and 7 including the start codon was removed using mouse insulin as a standard (Rat Insulin ELISA Kit, cat.
and replaced with a PGK-NEO-Poly(A) expression cassette (Adra et #INSKR020, Crystal Chem. Inc., Chicago, IL). Serum C-peptide lev-
al., 1987). The targeting plasmid was linearized and electroporated els were assessed using a Rat C-Peptide RIA Kit (cat. #RCP-21K,
into J1 embryonic stem cells (Li et al., 1993) provided by E. Li, A. Linco Res. Inc., St. Charles, MO).
Sharp, and R. Jaenisch. Targeted clones were identified by Southern
blot analysis using SacI digestion of ES cell genomic DNA and a
labeled SphI-SacI DNA fragment derived from a region 3 of the Hyperglycemic Clamp Studies
targeting construct as a hybridization probe (Figure 1a). Cells ex- Hyperglycemic clamp studies were performed using chronically
panded from targeted ES clones were injected into C57BL6 blasto- cannulated, fasted (5/6 hr), conscious male wild-type and knockout
cysts and germline transmitting chimeric animals were obtained and mice (16 to 22 weeks of age) as previously described (Kim et al.,
then mated with C57BL6 mice. The resulting heterozygous offspring 2000). The protocol included a 60 min basal period (60 to 0 min)
were crossed to generate wild-type (/), heterozygous (/), and and a 90 min hyperglycemic period (0 to 90 min). A variable infusion
homozygous (/) study subjects. Southern blot analysis and multi- of a 25% glucose solution was started at time 0 and periodically
plex PCR were employed to genotype mice. Primers used to detect adjusted to sequentially clamp the glucose concentration around
the KO allele were sense, 5cctccactcatgatctatagatc 3, located in 300 mg/dl. Plasma glucose concentrations were measured by the
the neo cassette, and antisense, 5accctctgtcgccaccatagtca 3, lo- glucose oxidase method (Beckman Glucose Analyzer 2, Fullerton,
cated in the Ucp2 coding sequence. Primers used to detect the CA). Additional blood samples were collected for measurement of
wild-type allele were sense, 5 gcactgcggcctgttttg 3, and the same plasma insulin (RIA kit, Linco Research, St. Charles, MO) at 10
antisense primer described above. and 0 min for the basal value, then at 5 min intervals until 30 min
Unless otherwise indicated, animals were housed 3–4 per cage and at 60 and 90 min. During both periods, a prime-continuous
in a temperature controlled room (23C) with a 12 hr light/dark cycle infusion of HPLC-purified [3-3H]glucose (New England Nuclear, Bos-
and had ad libitum access to chow (Rodent Diet #8664, Harlan ton, MA; 10 Ci bolus and 0.1 Ci/min) was maintained for assess-
Teklad, Madison, Wisconsin) and water. Animals were handled in ment of glucose turnover rates. Plasma samples for determination
accordance with the principles and guidelines established by the of [3H]glucose-specific activity were obtained at 10, 0 min during
National Institutes of Health. the basal period, and at 30, 60, and 90 min during the steady-state
clamp period. Analysis of [3H]glucose measurements and calculation
UCP2 Northern and Immunoblotting Studies of glucose-disposal rates and hepatic glucose production rates
Northern blot analysis was performed using a full-length rat Ucp2 were performed as described (Kim et al., 2000). At the end of the
cDNA hybridization probe. For detection of UCP2 protein in isolated clamp, mice were euthanized with sodium pentobarbital injection.
mitochondria, immunoblotting was performed using 40 g of mito- The Animal Care and Use Committee of Yale Medical School ap-
chondrial protein, goat anti-UCP2 IgG (UCP2 (C-20): sc-6525, Santa proved the hyperglycemic clamp studies.
Cruz Biotechnology, Inc, Santa Cruz, CA) as the first antibody (1:100)
and donkey anti-goat IgG (cat. #PA42005, Amersham Pharmacia
Biotech, Inc., Piscataway, NJ) as the second antibody (1:1000). For Creating ob/ob Mice Lacking UCP2
Ucp2 / and ob/ (Jackson Laboratories, Bar Harbor, ME) micedetection of UCP2 protein in islets, islet homogenates were pre-
pared. Two mg of homogenate protein was incubated overnight with were crossed to generate double heterozygotes. These double het-
erozygotes were then crossed to generate the following animals of2 g of goat anti-UCP2 IgG (sc-6525) coupled to protein G-seph-
arose. The immunoprecipitates were washed, resolved by SDS- which the males were collected and further studied: wild-type mice
(/ at both the ob and Ucp2 loci), ob/ob mice (ob/ob at the obPAGE, and transferred to nitrocellulose. UCP2 was detected using
rabbit anti-UCP2 antibody (cat. #662047, Calbiochem-Novabiochem locus and / at the Ucp2 locus), and ob/ob/ko mice (ob/ob at the
ob locus and / at the Ucp2 locus). The ob allele was genotypedCo., San Diego, CA) as first antibody (1:1000) and donkey anti-rabbit
IgG (cat. #NA 934) as the second antibody (1:2000). -tubulin was as previously described (Chung et al., 1997).
Cell
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